While increased healthcare spend will likely lead to higher revenues for manufacturers, life sciences companies will focus heavily on addressing ...

As pharmaceutical companies introduce new therapies to the U.S. market, they respond to risk-sharing agreements (RSAs) from healthcare providers, which ...

Developing data strategies for the storage, analysis and protection of patient-specific data has never been more critical to the future ...

As the global population grows increasingly focused on quality of life, many are also taking an active role in monitoring ...

To explore our 2015 Life Sciences Trends Report, download the PDF here or view an abbreviated overview below. In 2015, ...

Clarkston Consulting attended the Generic Pharmaceutical Association (GPhA) Annual Meeting earlier this month in Miami, Florida. This annual meeting is the ...

An article published this month in New York Magazine highlights the recent advancements to the regenerative medicine and medical device ...

Based on estimates from industry analysts, the market for biosimilars could grow to $24B by 2019. However, despite efforts by ...

Healthcare reforms, shifting market demands, and increasing regulatory pressures are transforming the life sciences industry on a global scale. Patients, ...

Regulatory pressures are adding layers of complexity to business decisions, pharma companies are increasingly leaning on biotechs to supplement their ...

The 2nd International Summit on GMP, GCP & Quality Control took place recently at the DoubleTree by Hilton Hotel Chicago ...

The annual meeting of the Bio Supply Management Alliance was held on October 8th, 2013, and was well-attended by key ...